Introduction
Pemphigus foliaceus (PF) is an autoimmune skin disease of humans and animals directed against keratinocyte adhesion proteins critical for cell-cell adhesion in the upper epidermis. 1, 2 In dogs, PF represents the most common autoimmune skin disease, and it is characterized by superficial pustules that affect predominantly the face, nasal planum and ears. When more generalized, lesions on the trunk accompany the classic involvement of the face and/or footpads, the latter being a unique location present in approximately one-third of dogs with PF.
In canine PF, desmocollin-1 (DSC1) represents a major target autoantigen, and antibodies were detected in approximately 75% of screened cases. 3 Desmoglein-1 (DSG1), the second critical desmosomal protein in the upper epidermis and the major target autoantigen in human PF, appears to be recognized by only a minority of tested dogs with PF. 4 Although the pathogenic significance of anti-DSC1 or anti-DSG1 IgG autoantibodies in canine PF has not yet been demonstrated, the pathogenic nature of the total antikeratinocyte IgG has been documented by passive transfer experiments in neonatal mice. 5 Factors that induce pathogenic autoantibodies in PF are largely unknown. While the genetic background plays an important role, one or more exogenous factors have been proposed to trigger this disease. 6 Of the possible external factors, drugs are the best-recognized triggers of pemphigus in humans, 7 and they are the most frequently proposed triggers in reports of canine PF. [8] [9] [10] [11] [12] In veterinary clinical settings, however, a systematic approach to determine the cause of a drug reaction (e.g. the use of the Naranjo drug probability scale) is rarely implemented and, therefore, most reported cases of drug-triggered canine PF remain unsubstantiated. An exception to this assertion is the recent report of drug-triggered PF by a flea preventative pesticide containing metaflumizone and amitraz (Promeris Duo; Pfizer, New York, NY, USA), in which 40% of affected dogs received the highest possible Naranjo score (i.e. 10 points) and were thereby diagnosed to have a definitive adverse drug reaction (ADR). Of the remaining dogs, one had a score of 9 points, while five dogs with localized and seven with distant disease were given a score of 7 (a probable ADR). 12 Regrettably, owing to the complex composition of this product, the authors were unable to identify which of the component (s) of the formulation (metaflumizone, amitraz and/or vehicle) probably triggered PF in affected dogs. 12 Interestingly, pesticides have been suggested as one of the possible triggers of pemphigus in people for decades. 6, [13] [14] [15] Possible pathomechanisms for pesticidetriggered pemphigus include the blocking of keratinocyte nicotinic acetylcholine receptor signalling involved in epidermal cohesion 16 and/or an enhanced cytokine production and neoantigen formation leading to an immune imbalance and autoimmunity in genetically predisposed individuals.
14 Although neither of the two insecticides included in Promeris Duo â , metaflumizone or amitraz, is known to have cholinergic properties, the effect of these insecticides or the accompanying vehicle on keratinocytes and the immune system has not been investigated to determine which individual component, or their combination, could trigger PF. [17] [18] [19] Certifect (Merial, Duluth, GA, USA) is a novel topical flea and tick preventative containing fipronil, amitraz and S-methoprene. 20 Published studies preceding its release in 2011 reported high efficacy and no clinically relevant systemic or cutaneous ADR. [21] [22] [23] [24] However, shortly after the product was launched, the authors became aware of reports of possible PF-like drug reactions, similar to Promeris-triggered PF (PTPF). In order to characterize better the similarities or differences between these conditions, our objectives were to describe the clinical, histological and immunological features for 21 dogs that developed cutaneous lesions after application of Certifect.
Materials and methods

Case selection
Cases were identified through an e-mail request sent to the Vetderm Internet list (vetderm@lists.ncsu.edu). Dogs of any age, sex or breed were included if they presented with pustular or crusted lesions that first appeared at the site of application of Certifect. The referring veterinarians were asked to complete a questionnaire inquiring about the patient's signalment and relevant medical and drug history (e.g. history of autoimmune disease, preceding drug administration, history of Promeris Duo application, number and frequency of Certifect applications, time to development of lesions, lesion type and distribution). The Naranjo's scale was used to determine the drug reaction probability score, as previously reported. 12, 25 Only cases reaching at least five points (i.e. probable drug reactions) or higher were entered into this case series. Dogs with a previous history of an autoimmune skin disease were excluded. Dogs were excluded if they had received another systemic or topical drug for the first time during the month preceding the development of skin lesions. Based on the lesion distribution, the dogs were divided into the following two groups: (i) those with a localized phenotype (i.e. lesions exclusively localized at the site of application); and (ii) those with a generalized phenotype (i.e. lesions at areas distant but not contiguous to those seen at the application site).
Histopathology
Haematoxylin-and eosin-stained histological sections of skin biopsy samples collected by submitting clinicians were reviewed for histopathological changes. Biopsy slides were available for 19 of 21 cases, a cytology slide was available for one case, for which a skin biopsy procedure was not performed, and a biopsy report only was available for one case. Biopsy samples and the cytology sample were collected from Certifect application sites and from some distant skin sites that developed lesions. For each case, sections were reviewed to identify any histopathological changes by a board certified veterinary pathologist (K.E.L.), including those previously described for PTPF. 12 Histological changes were scored using a standard severity scale of minimal, mild, moderate and marked. Detailed histopathology methods are provided in Data S1 in Supplementary material.
Detection of tissue-bound and circulating antikeratinocyte antibodies
Using a previously described technique, paraffin sections were assessed for the presence of tissue-bound IgG, IgM and IgA antibodies and activated C3 complement deposits between keratinocytes of the lesional skin, using previously described methods. 12, 26 The presence of tissue-bound antibodies and C3 complement was described based on the following criteria: (i) the pattern (i.e. intercellular or cytoplasmic); (ii) the epidermal depth (i.e. superficial, deep or panepidermal); and (iii) the extent (i.e. patchy to diffuse). Indirect immunofluorescence testing of serum on healthy canine footpad and buccal mucosa tissue sections was used to detect antikeratinocyte IgG and IgA autoantibodies. Serum was collected from affected patients during active clinical disease. Detection of anti-desmocollin-1 and anti-desmoglein-1 IgG antibodies
All available sera were tested for immunoreactivity against recombinant canine DSC1 and DSG1 expressed on the surface of a DSC1-and DSG1-transfected 293T kidney epithelial cell line as previously described. 3 Additionally, all sera from affected dogs were tested on nontransfected 293T cells to rule out a nonspecific recognition of 293T cells unrelated to the transfection status. Transfected and nontransfected 293T cells were also tested with an anti-V5 tag antibody (Invitrogen, Carlsbad, CA, USA), which served as a positive control and to prove the successful transfection status, while five serum samples from healthy dogs served as negative controls. 3 A positive result was characterized by stippled, membranous immunofluorescence.
Results
Clinical summary
Twenty-one dogs matching selection criteria were identified between May 2012 and February 2013. One case was from England; all others were from the USA. Most dogs were middle-aged or old (range, 5.5-13 years; median, 9 years) females (female-to-male ratio of 2.5) and of a large size (median, 23 kg). The signalment data are summarized in Table 1 . Nine of 21 dogs were Labrador retrievers, while the remaining 12 dogs were of different breeds (whippet, Pomeranian, dachshund, Border collie, chow cross, Chihuahua cross, beagle, Chesapeake Bay retriever, miniature schnauzer, toy poodle and mixed breed). Six of 21 dogs (29%) exhibited lesions only at the site of application (localized phenotype), while 15 of 21 (71%) developed lesions at the site of application as well as at distant sites not contiguous with the site of Certifect application (generalized phenotype). The location of the distant lesions and their frequency are described in Table 1 . In both groups, the skin lesions consisted of pustules, erosions, crusts and alopecia; the latter two being the most commonly reported lesions (100 and 95%, respectively; Figure 1 ). Systemic signs, such as fever, anorexia and lethargy, were seen exclusively in dogs with a generalized phenotype ( Table 1) .
None of these dogs had received Promeris Duo in the past or had received a new medication in the month preceding the development of the skin lesions. One of six dogs with the localized phenotype and two of 15 dogs with the generalized phenotype reached a Naranjo score value of 9 (i.e. a definitive ADR), while the remaining 18 dogs scored 6 points (i.e. a probable ADR).
The number of Certifect applications prior to disease development varied from one to 15, with a median of three and two for the localized and generalized phenotypes, respectively. One or two applications of Certifect were sufficient to trigger disease in seven (33%) or six (29%) dogs, respectively (Table 1) . All dogs for which the 'time to lesion development' was reported developed lesions within a month of the last Certifect application. In two dogs with the localized phenotype, the owner noticed some skin lesions 1 day after the application of Certifect, while the other two localized cases, for which such information was provided, developed lesions within 14 and 29 days postapplication. Three of the dogs with the generalized phenotype developed lesions within a week of Certifect application, while in five dogs the lesions appeared between 14 and 28 days postapplication.
The treatment histories were available for all 21 dogs (Table S1 in Supplementary material). Eighteen dogs received oral glucocorticoids at an anti-inflammatory (13 of 18) or immunosuppressive dosage (five of 18) either as a monotherapy (five of 18) or in combination with other systemic (eight of 18) or topical immunomodulatory drugs (two of 18) or with a combination of both (three of 18). In the remaining three dogs, ciclosporin was the only systemic medication administered to treat the dog.
Follow-up information was available for all dogs (range, 2-11 months; median, 6 months). Seventeen of 21 dogs reached full disease remission, 11 of which did not require further treatment. The median time to complete remission for both groups was 2 months (Table S2 in Supplementary material). At the time of writing, eight of 21 dogs (three localized and five generalized) were still undergoing treatment with systemic glucocorticoids (two of eight), glucocorticoids and azathioprine (two of eight), azathioprine (two of eight) or ciclosporin (two of eight). Of note, five of eight dogs still receiving medications have only been treated for 2 (three of five), 6 (one of five) or 6 months (one of five); four of them being in full disease remission.
Two of the 15 dogs with generalized phenotype were euthanized. One of these dogs was euthanized due to a presumed gastric ulcer perforation, possibly related to treatment with prednisone and azathioprine. The other dog was treated with prednisone and ciclosporin, but euthanasia was elected several weeks after initial presentation.
Histopathology
Microscopic changes observed at local skin application sites for Certifect were similar to those that developed at distant skin sites. Evidence of epidermal pustule formation (Figure 2a ) with keratinocyte acantholysis was present in 18 of 19 cases for which histology was available and via cytology or histopathology report in one case each. In 16 cases, pustules were active and, in two cases, only resolving pustules were captured as crusts containing 'ghost' acantholytic keratinocytes. Both small and large subcorneal pustules were often present in the same case (12 of 16) but, in a few cases, pustules were only small (one of 16) or only large (three of 16), the latter spanning more than one follicular infundibulum. Pustules were predominately subcorneal, involved only the superficial epidermis (12 of 16), occasionally extended deep (Figure 3 ) to near the basal layer (four of 16), and involved follicular infundibula (Figures 2c  and 3 ) in several cases (12 of 16) where pustules were mostly minimal to mild and rarely marked. Pustules contained minimal to marked numbers of acantholytic keratinocytes, which only occasionally occurred in clusters (Figure 3) , and could be found in several cases with an eosinophilic perinuclear ring, which was presumed to consist of collapsed intermediate filaments (Figure 2c) . Pustules contained neutrophils, and it was common to find minimal to marked numbers of eosinophils (Figure 2c) within pustules (13 of 16). Pustules evolved to crusts, which were only sometimes layered (Figure 2d ) and often contained dried 'ghost' acantholytic cells (Figure 2b) . A few crusts contained minimal to mild haemorrhage. Minimal to mild, and rarely moderate, spongiosis was common (Figure 3) , often at the ventral margins of pustules. Epidermal necrosis bordered a few pustules (six of 16) and was minimal to mild, observed as a thin rim, one or two cells thick, or was rarely moderate to marked, observed as partial to full-thickness epidermal necrosis (Figure 4a,b) . In these and other cases, all or some acantholytic keratinocytes often appeared prematurely necrotic (Figure 3, inset) . Keratinocyte apoptosis was minimal (five to 10 cells) in the stratum spinosum and granulosum of the epidermis in two cases, where it was near a pustule, and was accompanied by rare lymphocytic satellitosis in one case and neutrophils in one case. Irregular epidermal hyperplasia in all cases ranged from minimal to marked, while most cases had minimal to mild, basket weave to laminated, orthokeratotic hyperkeratosis with minimal patchy parakeratosis. Inter- Figure 1 . Representative clinical lesions of dogs with the localized and generalized phenotypes of Certifect-triggered pemphigus foliaceus. All three dogs (two localized and one generalized) developed the first lesions at the site of application. These consisted of erythema, erosions, alopecia and crusting. In addition, the dog with the generalized phenotype developed alopecia and crusts at sites distant from the application site. Courtesy of Valerie Fadok, Nicole Marquardt and Mike Mihlfried. estingly, two cases had moderate, near diffuse parakeratosis. Shallow erosions were common, and ulcers were found in fewer cases (five of 19), sometimes associated with pustules and epidermal necrosis.
In the dermis, perivascular to interstitial inflammation was predominately lymphoplasmacytic and often contained neutrophils in mild to moderate numbers in cases with active pustule formation. Eosinophils were common in the dermis (13 of 19) and ranged from a few individual cells to large numbers that dominated the inflammatory infiltrate. Dermal oedema was absent in some cases and ranged from minimal to marked in others. Mild haemorrhage was occasionally captured.
Detection of tissue-bound antikeratinocyte antibodies by direct immunofluorescence
Paraffin-embedded skin sections from 19 cases were available for detection of keratinocyte-bound IgG, IgA and IgM antibodies and activated C3 using direct immunofluorescence ( Table 2 ). Deposition of IgG was detected in eight of 19 dogs, and it was characterized by patchy (four of eight) or diffuse web-like fluorescence (four of eight) outlining the keratinocyte contours of the upper (six of eight; Figure 5 ), lower (one of eight) or the entire epidermis (one of eight). Deposition of IgM was detected in the epidermis of three dogs with either a patchy, intercellular (one of three) or cytoplasmic pattern (two of three) localized below a pustule or crust. Activated complement and IgA were detected in one case as patchy, intercellular deposits in the epidermis below pustules or crusts.
Detection of circulating antikeratinocyte antibodies by indirect immunofluorescence
Serum sampels from 14 dogs were available for detection of circulating antikeratinocyte IgG and IgA antibodies (Table 3) . Circulating IgG antibodies binding to keratinocytes of the footpad epithelium were detected in sera of two of three and eight of 11 dogs with the localized and generalized phenotypes, respectively. An intercellular IgG immunofluorescence pattern was observed in the superficial layers of the epidermis in all but one case with the localized phenotype, in which the IgG deposition was localized to the basal and lower stratum spinosum levels ( Figure 5 ). Circulating IgA antibodies binding to keratinocytes of the footpad epithelium were detected in four of 14 sera. Three of the four samples exhibited cytoplasmic deposition of IgA localized in the basal and lowest stratum spinosum layers, while serum from one dog with the generalized phenotype yielded an intercellular fluorescence pattern in the upper layers of the epithelium. For all 14 sera, neither IgG nor IgA antibody binding was detected on epithelial cells of buccal mucosa.
Detection of anti-desmocollin-1 and anti-desmoglein-1 IgG antibodies
Anti-DSC1 IgG antibodies were detected in two of three and nine of 11 sera from dogs with the localized and generalized phenotypes, respectively (Table 3 and Figure 5 ). Ten of these 11 sera with anti-DSC1 IgG corresponded to those with antikeratinocyte IgG antibodies reported in the section above. The last serum sample with anti-DSC1 IgG antibodies exhibited negative results on indirect immunofluorescence using canine footpad and buccal mucosa.
Discussion
Our results support Certifect-triggered ADR being another contact-triggered PF that closely resembles the previously described PTPF. 12 Indeed, skin lesions characterized by pustules, erosions and crusts at the application site only (localized phenotype) or at distant skin areas in addition to the application site (generalized phenotype) were identical to those of PTPF. Although systemic signs such as lethargy, fever and anorexia were reported in both entities, it appears that these were less common in Certifect-triggered PF (CTPF) cases (64% in PTPF versus 43% in CTPF) and none was reported in the localized form of CTPF. As in PTPF, females were more numerous in this study (71%); however, a reference population was not available to determine the relative risk more precisely. In contrast to the PTPF, in which more than 90% of cases were large-breed dogs, CTPF cases showed more variability in size (62% large, 24% medium and 14% small).
Immunosuppressive treatment (e.g. prednisone/prednisolone ≥2 mg/kg/day and/or azathioprine) was required to treat 59 and 43% of dogs with PTPF and CTPF, respectively. In PTPF, the need for immunosuppression in the localized form was nearly twice less likely than in dogs with the generalized form. In contrast, the use of immunosuppression in CTPF was nearly equal between the localized and generalized groups (50 and 40%, respectively). This difference could be explained by a more proactive treatment approach by veterinarians familiar with PTPF, with the goal of achieving fast remission of clinical signs and to prevent potential progress into the generalized phenotype. Indeed, complete remission of clinical signs was observed in 81% of dogs with CTPF, with a median time to complete remission being approximately 2 months for both localized and generalized phenotypes. Moreover, in 11 of 21 dogs (52%), drugs could be fully discontinued. A similar rate of complete remission (86%) was reported in the PTPF case series but, in contrast to the CTPF, drugs were completely discontinued in a greater number of cases, 16 of 21 dogs (76%). This difference could be explained by the longer duration of followup in the PTPF study (median, 15 and 6 months for PTPF and CTPF, respectively).
Distinct differences in the types of histopathological skin lesions from dogs with CTPF, PTPF and natural PF were not discovered. The morphological spectrum and extent of tissue changes overlapped between these conditions. Therefore, histopathology by itself cannot readily distinguish between these three entities, and a thorough history and clinical assessment are crucial to render the correct diagnosis and provide an appropriate prognosis, the latter of which is poorer for natural PF. Information about topical drug application and any relationship to skin lesion development at the application site is needed. Biopsy and/or cytology of any contact-associated skin lesions caused by topically applied pesticide is recommended to look for evidence of pustule formation and keratinocyte acantholysis. In the CTPF, epidermal necrosis in association with pustule formation and premature necrosis of acantholytic keratinocytes were identified and are possible features that differentiate natural PF, if present. Additional findings of ulceration of the epidermis and minimal to mild haemorrhage in the crusts of some CTPF lesions also support previous full-thickness necrosis of the epidermis, which is not typical of natural PF, and might be indirect indicators of necrosis contributing to CTPF lesions. Further investigations are warranted to address patterns of necrosis in CTPF and their value as differentiating features from that of the natural PF.
Similar to cases of PTPF and natural PF, tissue-bound and circulating antikeratinocyte antibodies were detected in samples from dogs with CTPF independently of their phenotype status. Indeed, the percentage of dogs with circulating antikeratinocyte antibodies binding to the canine footpad substrate was very similar between dogs with localized and generalized CTPF phenotypes, which could have been the result of a small number of samples from dogs with the localized phenotype. These findings were further supported by the detection of circulating anti-DSC1 IgG antibodies in all sera with detectable tissue-bound or circulating antikeratinocyte antibodies. In general, the percentage of sera with anti-DSC1 reactivity in CTPF (71%) was similar to that reported for PTPF (75%) and natural PF (82%) in the recent publication Table 2 . Detection of tissue-bound antibodies and complement in the skin of dogs with the localized or generalized form of Certifecttriggered pemphigus foliaceus
Number (%) 0 (0) 1 (7) Figure 5 . Certifect-triggered pemphigus foliaceus. A composite depicting positive results of direct and indirect immunofluorescence studies demonstrating tissue-bound and circulating antikeratinocyte and anti-desmocollin-1 (anti-DSC1) IgG autoantibodies. establishing this protein as a major canine PF autoantigen. 3 The clinical, histological and immunological similarity between CTPF and natural PF suggests a shared pathogenesis for these conditions.
Little is known about the exact trigger leading to the antibody production and disease development in the PTPF and CTPF. Genetic background, immunological or hormonal status are all well-known factors that can influence development of natural pemphigus in humans. Considering the large number of dogs treated with Promeris Duo or Certifect and the relatively low number of reported cases of PTPF or CTPF, it is likely that these or other patient-specific factors are also involved in the development of these two conditions. It is currently unknown which of the components (amitraz, metaflumizone, fipronil or vehicles) or any combination thereof represents the trigger. To complicate this analysis, there is a recent report of contact-triggered PF after administration of yet another flea preventative containing completely different drugs (dinotefuran, pyriproxyfen and permethrin; Vectra 3D; Ceva Animal Health, Lenexa, KS, USA). 27 We speculate that insecticide contact-triggered pemphigus could be elicited by several mechanisms, including a systemic effect via absorption of the drug or by a direct alteration of the skin and formation of neoantigens, which, in susceptible individuals, could lead to a secondary production of autoantibodies. 28 Other mechanisms proposed in development of contact pemphigus comprise allergic contact reactions with enhanced cytokine release, activation or inhibition of enzymes involved in cell adhesion or an imbalance in cholinergic control of keratinocyte adhesion. 7, 16 Interestingly, two dogs in this series developed local skin lesions within a day and one within a week after receiving the first dose of Certifect. Given that the onset of the lesion was based on the owners' reports, it is unknown whether these early lesions corresponded to the acantholytic pustules seen in the CTPF or if they represented local inflammation with keratinocyte injury. The latter option is more likely, because the production of autoantibodies requires at least 3-4 weeks after the primary sensitization. 29 However, the rapid appearance of skin lesions could support the hypothesis of an initial keratinocyte injury leading to the release of autoantigens and/or to the establishment of a pro-inflammatory cytokine milieu, which, in predisposed dogs, could trigger a true autoimmune response.
Further studies to investigate factors such as the effect of the vehicles with or without the concurrent presence of the active ingredients on skin keratinocytes or adhesion proteins or on the induction of pro-inflammatory cytokines could help to uncover the mechanism by which these products cause this unique cutaneous ADR. One should, however, bear in mind that factors other than the drug are likely to be important for the development of this rare disease (e.g. genetic background, immunological or hormonal status and environment).
In conclusion, CTPF represents another contacttriggered PF, the awareness of which should be disseminated among veterinarians and owners. As a result of the variability in the number of monthly applications from one-to 15 before the disease onset, it is impossible to predict whether or not a dog might develop this cutaneous ADR. However, because skin lesions developed at the site of application within the first 2 weeks in more than half of the dogs (67%), the owners should be advised to observe application sites daily and to report any visible changes. Treatment should include a thorough washing of the dog (especially in early detected cases) and concurrent anti-inflammatory or immunosuppressive therapy as deemed appropriate. The choice of immunosuppression will depend on the severity of the disease and the response to an anti-inflammatory treatment (if previously tried). Topical glucocorticoids might be of help to manage focal lesions in both localized and generalized phenotypes.
Veterinarians and veterinary pathologists should be aware that histopathology does not readily distinguish natural PF from PTPF or CTPF and, therefore, that a thorough clinical history is critical for differentiating these conditions and for prognosis.
Finally, these unique cutaneous ADRs present an opportunity for studying contact-triggered pemphigus, which is a very rare condition in human medicine. Unravelling the mechanism of disease development would further increase the knowledge about keratinocyte adhesion and pemphigus development in veterinary and human dermatology; it would also help in designing flea preventatives with minimal risk for development of such unique cutaneous ADRs.
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